NTRB

Nutriband Inc. (NTRB) | Rumor.io

Nutriband

NTRB

Attention (50-day avg)0%

Attention rank (50-day avg)#1,965

Bullish sentiment (50-day avg)100%

Price to earnings ratio-3.2

Market capitalization100M

Earnings per share-0.6

Dividend yield (TTM)—

Revenue (annual)2M

Net income (annual)-8.2M

Social

What share of all stock conversation is about NTRB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 10

$NTRB is on the radar for a potential momentum move and an interesting setup ahead.
$NTRB is being closely watched by traders for its next move.
The bullish sentiment on $NTRB suggests a positive outlook for the asset.

Generated by AI

Sentiment

Of the messages about NTRB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	94.12% -0.48
Bearish	—	0% 0	0% 0	5.88% +0.48

Bullish· Jul 2

$NTRB has a strong chart with all 12 moving averages and 10 out of 11 technical indicators showing a buy signal, indicating a strong trend.
The company's lead product has sales potential of $80M to $200M in a market expected to reach $18B, with a price target set at $15.00 and multiple analysts labeling it a "Strong Buy".
The stock has rallied +28.4% on NDA filing and has a 25% preferred stock dividend, with the Russell index inclusion and FDA moves expected to drive the stock higher.

Bearish· Jan 11

Nutriband Inc. (NTRB) has high insider ownership, which may be a concern for investors.
The company's utilization rate is near 100%, which could indicate a potential issue with its operations.
NTRB has been the subject of a pump and dump scheme, with many investors experiencing significant losses after buying into the stock.

Generated by AI

Topics

Of the messages about NTRB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	78.57%	73.3%	58.36%
Technical Analysis	—	0%	0%	2.26%
Controversies	—	21.43%	26.7%	17.94%
Analysts	—	0%	0%	12.37%
Earnings	—	0%	0%	5.4%
Macro	—	0%	0%	3.66%

Announcements· Sep 9

Nutriband Inc. has cleared a key IP hurdle, naming its abuse-deterrent fentanyl patch.
The company is advancing its fentanyl patch brands through the USP process, a crucial step toward commercialization.
Nutriband received a USPTO Notice of Publication for commercial brand name trademarks associated with its lead abuse-deterrent fentanyl transdermal system.

Controversies· Sep 9

Nutriband Inc. has received a USPTO notice of publication for its commercial brand name trademarks for its abuse deterrent fentanyl patch.
The latest USPTO update is another development for Nutriband Inc. shareholders to consider.
Nutriband Inc.'s fentanyl patch is an abuse deterrent, a feature that aims to reduce the risk of opioid addiction and overdose.

Technical Analysis· Jan 11

$NTRB has broken the 21/50ema on the 1-day chart, offering a good risk/reward for a potential swing trade.
A bid wall is visible around 7.8, and a ceiling at 8.34, with a screenshot from TDA's bookmap showing overall net buying for the day.
$NTRB is printing a cup and handle pattern, with the handle almost complete, and a golden cross on the 15-minute chart.

Generated by AI

Community

Of the messages about NTRB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	21.43%	3.53%	16.25%
Newcomers	—	78.57%	96.47%	83.75%

Regulars· Jan 22

The price of $NTRB has been volatile, with the stock reaching $7 in late January, causing some to sell their shares.
Despite previous losses, some regular traders have been able to hold onto their $NTRB shares and even sell them at a profit, with one trader selling at $3.20.
The halt in trading for $NTRB has occurred, with one trader noting that it's the first time this has happened, and encouraging followers to seek out more information and catalysts.

Newcomers· Sep 10

$NTRB is catching the attention of traders with its interesting setup ahead, potentially leading to a momentum move.
Nutriband Inc. ($NTRB) is being closely watched by traders who are keeping a close eye on the ticker.
Traders are keeping $NTRB in focus, waiting for the next move, as they monitor the company's momentum.

Generated by AI

News

Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis

21h agoYahoo! Finance Canada

Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing

7d agoYahoo Finance

Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit

ORLANDO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO, Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th. The Summit brings together biotechnology executives, investors, and industry leaders for an evening of thought leadership and networking at Nasdaq MarketSite in New York. About AVERSA™ Abuse-Deterrent Transdermal Technology Nutriband's AVERSA™ abuse-deterrent transdermal technology incorp

21d agoYahoo Finance

Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch

Nutriband has received a Notice of Publication from the United States Patent and Trademark Office (USPTO) for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transdermal system. Once allowed, Nutriband plans to submit its commercial worldwide brand name to the FDA and other international regulatory agencies for approval. ORLANDO, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescrip

22d agoYahoo Finance

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

ORLANDO, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO and Co-Founder, Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit on Aug 26th as part of the CEO spotlight event. The Georgia Life Sciences Summit brings together leaders from across biotechnology, medical technology, research, manufacturing, and investment to showcase Georgia’s emergence as a national leader in life sciences innovation. The Summit takes p

1mo agoYahoo Finance

Noble Financial Keeps Their Buy Rating on Nutriband (NTRB)

Detailed price information for Nutriband Inc (NTRB-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about NTRB also mention

#	Name	Attention
1	Immix Biopharma, Inc.IMMX	0.03%+0.03
2	Society Pass IncorporatedSOPA	0%0
3	TSRI - TSR, Inc.	——
4	Longeveron Inc. Class A Common StockLGVN	0%0
5	GRTX - Galera Therapeutics, Inc.	——
6	Biofrontera Inc.BFRI	0%0
7	FATH - Fathom Digital Manufacturing Corporation	——
8	Nutriband Inc.NTRBW	0%0
9	Lendway Inc.LDWY	0%new
10	DNAY - Codex DNA, Inc.	——

Nutriband Inc.

Healthcare
Biotechnology

Nutriband Inc. is a pharmaceutical company focused on the development of transdermal drug delivery products. The company’s core work centers on abuse-deterrent patch technologies designed to reduce the risk of misuse, diversion, and accidental exposure for drugs with abuse potential, particularly opioids. Its lead development program is AVERSA Fentanyl, alongside additional transdermal products such as AVERSA Buprenorphine and AVERSA Methylphenidate. Nutriband also operates through business segments that include pharmaceuticals and medical devices, supporting both product development and related manufacturing activities. Based in Orlando, Florida, Nutriband serves the healthcare market by advancing patch-based therapies that aim to deliver medications through the skin in a controlled and convenient format.

Website

Location

121 South Orange Avenue

Orlando, FL, 32801

United States

Social

What share of all stock conversation is about NTRB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 10

$NTRB is on the radar for a potential momentum move and an interesting setup ahead.
$NTRB is being closely watched by traders for its next move.
The bullish sentiment on $NTRB suggests a positive outlook for the asset.

Generated by AI

Sentiment

Of the messages about NTRB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	94.12% -0.48
Bearish	—	0% 0	0% 0	5.88% +0.48

Bullish· Jul 2

$NTRB has a strong chart with all 12 moving averages and 10 out of 11 technical indicators showing a buy signal, indicating a strong trend.
The company's lead product has sales potential of $80M to $200M in a market expected to reach $18B, with a price target set at $15.00 and multiple analysts labeling it a "Strong Buy".
The stock has rallied +28.4% on NDA filing and has a 25% preferred stock dividend, with the Russell index inclusion and FDA moves expected to drive the stock higher.

Bearish· Jan 11

Nutriband Inc. (NTRB) has high insider ownership, which may be a concern for investors.
The company's utilization rate is near 100%, which could indicate a potential issue with its operations.
NTRB has been the subject of a pump and dump scheme, with many investors experiencing significant losses after buying into the stock.

Generated by AI

Topics

Of the messages about NTRB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	78.57%	73.3%	58.36%
Technical Analysis	—	0%	0%	2.26%
Controversies	—	21.43%	26.7%	17.94%
Analysts	—	0%	0%	12.37%
Earnings	—	0%	0%	5.4%
Macro	—	0%	0%	3.66%

Announcements· Sep 9

Nutriband Inc. has cleared a key IP hurdle, naming its abuse-deterrent fentanyl patch.
The company is advancing its fentanyl patch brands through the USP process, a crucial step toward commercialization.
Nutriband received a USPTO Notice of Publication for commercial brand name trademarks associated with its lead abuse-deterrent fentanyl transdermal system.

Controversies· Sep 9

Nutriband Inc. has received a USPTO notice of publication for its commercial brand name trademarks for its abuse deterrent fentanyl patch.
The latest USPTO update is another development for Nutriband Inc. shareholders to consider.
Nutriband Inc.'s fentanyl patch is an abuse deterrent, a feature that aims to reduce the risk of opioid addiction and overdose.

Technical Analysis· Jan 11

$NTRB has broken the 21/50ema on the 1-day chart, offering a good risk/reward for a potential swing trade.
A bid wall is visible around 7.8, and a ceiling at 8.34, with a screenshot from TDA's bookmap showing overall net buying for the day.
$NTRB is printing a cup and handle pattern, with the handle almost complete, and a golden cross on the 15-minute chart.

Generated by AI

Community

Of the messages about NTRB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	21.43%	3.53%	16.25%
Newcomers	—	78.57%	96.47%	83.75%

Regulars· Jan 22

The price of $NTRB has been volatile, with the stock reaching $7 in late January, causing some to sell their shares.
Despite previous losses, some regular traders have been able to hold onto their $NTRB shares and even sell them at a profit, with one trader selling at $3.20.
The halt in trading for $NTRB has occurred, with one trader noting that it's the first time this has happened, and encouraging followers to seek out more information and catalysts.

Newcomers· Sep 10

$NTRB is catching the attention of traders with its interesting setup ahead, potentially leading to a momentum move.
Nutriband Inc. ($NTRB) is being closely watched by traders who are keeping a close eye on the ticker.
Traders are keeping $NTRB in focus, waiting for the next move, as they monitor the company's momentum.

Generated by AI

Nutriband

Social

Sep 10

Bullish· Jul 2

Bearish· Jan 11

Announcements· Sep 9

Controversies· Sep 9

Technical Analysis· Jan 11

Regulars· Jan 22

Newcomers· Sep 10

Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis

Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing

Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit

Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

Noble Financial Keeps Their Buy Rating on Nutriband (NTRB)

Also Discussed

Nutriband Inc.

Company Information

Location

Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis

Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing

Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit

Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch

Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight

Noble Financial Keeps Their Buy Rating on Nutriband (NTRB)

Also Discussed

Social

Sep 10

Bullish· Jul 2

Bearish· Jan 11

Announcements· Sep 9

Controversies· Sep 9

Technical Analysis· Jan 11

Regulars· Jan 22

Newcomers· Sep 10